News | April 03, 2021
Reports on GSK Pharmaceuticals by ICICI Securities
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Subscribe To Our Newsletter & Stay Updated
